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Beclomethasone and Albuterol in Mild Asthma
To the Editor: In the study of rescue use of beclomethasone and albuterol in a single inhaler for mild asthma reported by Papi et al. (May 17 issue) , 1 the morning peak expiratory flow rate (based on peak-flow diaries) was the primary end point, although there is enough reason to doubt its clinical relevance, its validity, and its physiological meaning in a disease that predominantly affects smaller airways. The peak expiratory flow rate reflects mainly central-airway mechanics 2 and is insensitive for the monitoring of peripheral-airway patency. Only because no Bonferroni correction was used, the morning peak expiratory flow rate -but not the evening peak expiratory flow rate or variability in peak expiratory flow rate -was marginally significantly different (P = 0.04) between the as-needed combination group and the as-needed albuterol group, whereas the secondary end points of forced expiratory volume in 1 second and forced vital capacity (percent of the predicted value) proved to be much more sensitive in detecting a treatment effect. A similar situation was reported previously, 3 and the study by Papi et al. once again illustrates that measures of peak expiratory flow rate are insensitive and therefore, in my opinion, do not reflect the disease adequately. The Authors Reply: Merkus is concerned that the use of the morning peak expiratory flow rate, based on peak-flow diaries, may be misleading because it is insensitive and may not reflect small-airway abnormalities. Measurement of the peak expiratory flow rate is still recommended in international guidelines 1 for monitoring asthma. It is incorrect to state that the peak expiratory flow rate did not differ significantly between the groups in our study, since the morning peak expiratory flow rate was indeed sensitive enough to detect significant differences, in direct comparisons of the experimental treatment (as-needed use of combination albuterol-beclomethasone and regular use of beclomethasone) and the control treatment (as-needed use of albuterol). To the best of our knowledge, there is no single test of airway function that reflects the prevalent site of airflow obstruction in asthma, and there is no evidence from clinical trials that physiological measures that are thought to reflect peripheral airways correlate better with respiratory symptoms than other tests of airway function. 2 We agree that since the objective of asthma treatment is to ensure clinical control, it would be of value to design trials that involve patientcentered outcomes. 3 We also agree with Terracciano and colleagues that treatments for asthma should be tested in children with mild asthma. A randomized clinical trial sponsored by the National Heart, Lung, and 
